8 To 10 Amino Acid Residues In Defined Sequence Patents (Class 530/328)
-
Patent number: 8956878Abstract: The present application is directed to a peptides comprising an a-helix forming-amino acid sequence that binds a heat shock protein. Also included is a polypeptide comprising (a) a first peptide portion that comprises an ?-helix-forming amino acid sequence that binds a heat shock protein; and (b) at least one second peptide portion comprising an antigenic amino acid sequence and/or an a-helix-stabilizing amino acid sequence that increases the interaction of the first peptide portion with the heat shock protein. The present application also includes compositions comprising the peptides and/or polypeptides of present application and uses of the peptides and/or polypeptides of the present application for fractionating substances relevant for discovery, research or clinical analysis from a biological sample and as therapeutics.Type: GrantFiled: March 21, 2012Date of Patent: February 17, 2015Assignees: Atlantic Cancer Research Institute, New England Peptide, Inc.Inventors: Steven Gareth Griffiths, Scott Edwin Lewis
-
Patent number: 8957032Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.Type: GrantFiled: May 6, 2009Date of Patent: February 17, 2015Assignee: Alba Therapeutics CorporationInventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
-
Patent number: 8957030Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: GrantFiled: February 27, 2013Date of Patent: February 17, 2015Assignees: Cornell Research Foundation, Inc., Institute de Recherches Cliniques de MontrealInventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
-
Publication number: 20150045291Abstract: The invention provides conjugates comprising a short isolated peptide coupled to a sphingolipid, the peptide comprising a sequence derived from the HIV-1 gp41. The sphingolipid-peptide conjugates are suitable for treatment of infections caused by human and non-human retroviruses, especially HIV.Type: ApplicationFiled: April 3, 2013Publication date: February 12, 2015Inventors: Yechiel Shai, Avraham Ashkenazi
-
Publication number: 20150044703Abstract: Some embodiments of the present invention relate to methods and compositions for detecting the presence of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.Type: ApplicationFiled: March 12, 2013Publication date: February 12, 2015Applicant: University of South AlabamaInventors: Michael A. Finan, Rodney P. Rocconi, Lewis K. Pannel
-
Publication number: 20150045506Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.Type: ApplicationFiled: March 18, 2013Publication date: February 12, 2015Applicants: UNIVERSITE LILLE 2 DROIT ET SANTE, INSTITUT PASTEUR DE LILLEInventors: Oleg Melnyk, Laurent Raibaut, Nathalie Ollivier
-
Publication number: 20150045283Abstract: The present invention provides novel PAR lderived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met1-Arg46 deleted human PAR 1 sequence. These cytoprotective oligopeptides or polypeptides are capable of activating PAR 1 and promoting PAR 1 cytoprotective signaling activities. The invention also provides engineered cells or transgenic non-human animals which harbor in their genome an altered PAR 1 gene that is resistant to cleavage at Arg41 and/or Arg46 residues. Additionally provided in the invention are methods of screening candidate compounds to identity additional cytoprotective compounds or cytoprotective proteases. The invention further provides therapeutic use or methods of employing a PAR 1 derived cytoprotective oligopeptide or polypeptide to treat conditions associated with tissue injuries or undesired apoptosis.Type: ApplicationFiled: November 7, 2012Publication date: February 12, 2015Inventors: Laurent O. Mosnier, John H. Griffin
-
Patent number: 8951963Abstract: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. The invention also provides an antibody to the peptide triazole conjugate. The invention further provides a method of identifying an HIV-1 entry inhibitor candidate.Type: GrantFiled: March 27, 2013Date of Patent: February 10, 2015Assignee: Drexel UniversityInventors: Irwin M. Chaiken, Umashankara Muddegowda, Karyn McFadden
-
Patent number: 8952128Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.Type: GrantFiled: October 31, 2013Date of Patent: February 10, 2015Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Yeelana Shen, Sun Hyuk Kim
-
Patent number: 8952127Abstract: The present invention provides for a bio-mimetic polymer capable of catalyzing CO2 into a carbonate.Type: GrantFiled: June 3, 2011Date of Patent: February 10, 2015Assignee: The Regents of the University of CaliforniaInventors: Chun-Long Chen, Ronald N. Zuckermann, James J. De Yoreo
-
Patent number: 8951975Abstract: Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.Type: GrantFiled: March 30, 2011Date of Patent: February 10, 2015Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20150038435Abstract: The present invention is related to N-terminally fatty acid modified peptides or oligopeptides and pharmaceutical compositions comprising such.Type: ApplicationFiled: March 1, 2013Publication date: February 5, 2015Inventor: Frantisek Hubalek
-
Publication number: 20150038675Abstract: The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride.Type: ApplicationFiled: February 12, 2013Publication date: February 5, 2015Inventors: Yoichi Kumada, Michimasa Kishimoto, Takeru Otsuka
-
Publication number: 20150038676Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.Type: ApplicationFiled: July 24, 2014Publication date: February 5, 2015Inventors: FRIEDRICH SCHEIFLINGER, MICHAEL DOCKAL
-
Patent number: 8946150Abstract: The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.Type: GrantFiled: June 14, 2012Date of Patent: February 3, 2015Assignee: Medical Diagnostic Laboratories, LLC.Inventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Patent number: 8945578Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.Type: GrantFiled: December 31, 2013Date of Patent: February 3, 2015Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Publication number: 20150031851Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.Type: ApplicationFiled: October 30, 2013Publication date: January 29, 2015Applicant: SANFORD-BUMHAM MEDICAL RESEARCH INSTITUTEInventors: ERKKI RUOSLAHTI, KIMMO PORKA, SVEN CHRISTIAN
-
Patent number: 8940864Abstract: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.Type: GrantFiled: October 2, 2007Date of Patent: January 27, 2015Assignee: New York Blood Center, Inc.Inventors: Asim Kumar Debnath, Hongtao Zhang, Qian Zhao
-
Patent number: 8940545Abstract: A method for screening a drug for cytochrome P450 (CYP) induction is provided and can include incubating the drug with a microsome-containing biological sample and then quantitating at least one cytochrome P450 isoform. The isoforms can be selected from 2B6, 3A4, 1A2, and 3A5 isoforms. In some embodiments, the method uses liquid chromatography tandem mass spectrometry (LC-MSMS). A quantitated value can be compared to a threshold value and the drug can be determined to exhibit an acceptable CYP induction potential when the quantitated value does not exceed the threshold value. Isolated peptides are also provided.Type: GrantFiled: October 14, 2010Date of Patent: January 27, 2015Assignee: DH Technologies Development Pte. Ltd.Inventors: Brian L. Williamson, Subhasish Purkayastha
-
Patent number: 8940865Abstract: Disclosed are two myocardial peptides, whose amino acid sequences are Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe and Lys-Gly-Ala-Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe respectively, wherein the latter can be obtained by extracting from myocardial peptides solution. The myocardial peptides can be used in the produce of a medicament for preventing and/or treating myocardial ischemia.Type: GrantFiled: July 15, 2008Date of Patent: January 27, 2015Assignee: Dalian Zhen-Ao Pharmaceutical Co, Ltd.Inventors: Yusong Chen, Shu Li, Risheng Wang, Qiang Liang, Zheng Zeng, Xiaohong Qian, Dong Cao, Huimin Liang
-
Publication number: 20150024380Abstract: The invention relates to novel interfering peptides having peptide sequence S with between 7 and 12 amino acids, originating from the peptide sequence of an antigenic protein of a micro-organism M, the sequence S being aligned with a peptide sequence S? with between 7 and 12 amino acids originating from the peptide sequence of a target protein of a micro-organism M? that is different from the micro-organism M, provided that: sequences S and S? have at least 50% identity over their length of 7 to 12 amino acids and at least 4 identical or analogous contiguous amino acids; and their length is identical or they have 1 or 2 different amino acids distributed at one and/or the other end of the sequences. The invention also relates to a method for the in vitro immunoassay-based detection of the presence of a micro-organism M? or M in a biological sample.Type: ApplicationFiled: March 11, 2013Publication date: January 22, 2015Inventors: Florence Bettsworth, Catherine Pothion, Béatrice Seigneres
-
Publication number: 20150025005Abstract: A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia.Type: ApplicationFiled: February 19, 2013Publication date: January 22, 2015Applicant: Massachusetts Institute of TechnologyInventors: Robert S. Langer, Daniel G. Anderson, Zhen Gu, Alex Arthur Aimetti
-
Publication number: 20150023991Abstract: The present invention concerns the field of tumor therapeutics and diagnostics. Specifically, it relates to a peptide comprising at least 8 amino acids in length which are present as contiguous amino acid sequence in the human Isocitratdehydrogenase Type 1 (IDH1), wherein said peptide has at least one amino acid exchange from R to H at a position corresponding to position 132, for use in preventing and/or treating cancer. Further contemplated is a medicament comprising the said peptide.Type: ApplicationFiled: January 3, 2013Publication date: January 22, 2015Inventors: Michael Platten, Theresa Schumacher, Wolfgang Wick
-
Publication number: 20150023957Abstract: Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.Type: ApplicationFiled: July 9, 2014Publication date: January 22, 2015Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventors: Haichao Wang, Andrew E. Sama, Wei Li, Kevin J. Tracey
-
Publication number: 20150025221Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.Type: ApplicationFiled: April 25, 2014Publication date: January 22, 2015Applicant: The Regents of the University of CaliforniaInventors: Tracy Hsu, Samir M. Mitragotri
-
Patent number: 8937154Abstract: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.Type: GrantFiled: February 2, 2012Date of Patent: January 20, 2015Assignee: New York Blood Center, Inc.Inventors: Asim Kumar Debnath, Hongtao Zhang, Qian Zhao
-
Publication number: 20150017259Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.Type: ApplicationFiled: August 21, 2014Publication date: January 15, 2015Inventors: LORI HAZLEHURST, MARK MCLAUGHLIN, PRIYESH JAIN, WILLIAM S. DALTON
-
Publication number: 20150017148Abstract: In certain embodiments compositions are provided that comprise a pentapeptide comprising the formula: C1-X2-X3-X4-C5 where C1 and C5 are independently selected cysteines or cysteine analogues, or other amino acids with sidechains suitable for cyclization, where the cysteines or cysteine analogs are attached to each other by a linkage that does not comprise X2, X3, and X4; where X2, X3, and X4 are independently selected amino acids; and the peptide, when administered to a cell alters APP signaling and/or switches APP processing from aberrant to normal. The compositions mitigate amyloid plaque formation.Type: ApplicationFiled: November 27, 2012Publication date: January 15, 2015Inventors: Varghese John, Clare Peters-Libeu, Dale E. Bredesen
-
Publication number: 20150018224Abstract: The invention provides an isolated peptide comprising a lysine 2-hydroxyisobutyrylation site, a lysine 2-hydroxyisobutyrylation specific affinity reagent that specifically binds to the peptide, and a method for detecting protein lysine 2-hydroxyisobutyrylation in a sample using the reagent.Type: ApplicationFiled: July 15, 2013Publication date: January 15, 2015Inventors: Yingming ZHAO, Lunzhi Dai
-
Publication number: 20150018269Abstract: The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.Type: ApplicationFiled: August 24, 2012Publication date: January 15, 2015Applicants: UNIVERSITÄT ZU KÖLN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Ronald Kühne, Hartmut Oschkinat, Robert Opitz, Matthias Müller, Hans-Günther Schmalz, Cedric Reuter, Peter Huy
-
Publication number: 20150017665Abstract: The present invention relates to disorder-specific epitopes recognized by myeloperoxidase-anti-neutrophil cytoplasmic autoantibodies and the use of polypeptides comprising the epitopes in methods of diagnosing and monitoring autoimmune disorders associated with the autoantibodies.Type: ApplicationFiled: January 3, 2013Publication date: January 15, 2015Applicant: The University of North Carolina at Chapel HillInventors: Ronald Falk, Aleeza Roth
-
Patent number: 8933038Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.Type: GrantFiled: December 31, 2013Date of Patent: January 13, 2015Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Patent number: 8933014Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.Type: GrantFiled: March 10, 2011Date of Patent: January 13, 2015Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Patent number: 8933035Abstract: A peptide of general formula (I): R1-(AA)nX1-X2-Arg-Arg-Gly-X3-X4-(AA)p-R2, and cosmetic and pharmaceutical compositions are disclosed that include at least one peptide of general formula (I), in a physiologically suitable medium. Also disclosed are methods for activating human transglutaminase to reinforce the skin barrier function and to stimulate epidermal regeneration and differentiation or for cosmetic treatment to treat signs of skin ageing, which include administering a composition containing the peptide of general formula (I) as an active ingredient.Type: GrantFiled: August 31, 2010Date of Patent: January 13, 2015Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8933194Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.Type: GrantFiled: May 16, 2012Date of Patent: January 13, 2015Assignee: Palatin Technologies, Inc.Inventors: Wei Yang, Yi-Qun Shi
-
Publication number: 20150011465Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.Type: ApplicationFiled: September 9, 2014Publication date: January 8, 2015Inventors: Kent Kirshenbaum, Sung Bin Shin
-
Publication number: 20150011477Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys or Thr-Phe-Leu-Lys-Cys, useful as a CCR2 non competitive antagonist peptide.Type: ApplicationFiled: June 26, 2012Publication date: January 8, 2015Applicant: UNIVERSITE PIERRE ET MARIE CURIEInventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvain Chemtob, Christiane Quiniou
-
Patent number: 8927489Abstract: The present invention provides a pharmaceutical composition for the sustained release of C-peptide. The composition is in the form of a gel containing C-peptide. The gel formation is achieved by the adjustment of pH of the composition and/or by addition of divalent metal ions. The composition does not include any other gel-forming agents. Methods for producing the composition, medical uses of the composition and products containing two or more gel compositions as a combined preparation are also encompassed.Type: GrantFiled: June 2, 2006Date of Patent: January 6, 2015Assignee: Cebix IncorporatedInventors: John Wahren, Anders Carlsson
-
Patent number: 8927688Abstract: PAR4 agonist peptides are disclosed. These peptides are useful for developing robust PAR4 receptor assays.Type: GrantFiled: April 24, 2013Date of Patent: January 6, 2015Assignee: Bristol-Myers Squibb CompanyInventors: Michael G. Kornacker, Claudio Mapelli, Douglas James Riexinger
-
Publication number: 20150004698Abstract: Disclosed herein is a species of peptide and non-peptide inhibitors of Akt, an oncogenic protein. Beginning with a residue of Akt target substrate GSK-3, the functional domains of the GSK-3 residue were characterized. Functionally homologous non-peptide groups were substituted for the amino acids of the GSK-3 creating a hybrid peptide-non-peptide and non-peptide compounds capable of binding to Akt. The non-peptide compounds show increased stability and rigidity compared to peptide counterparts and are less susceptible to degradation. The bound non-peptide compounds exhibit an inhibitory effect on Akt, similar to peptide-based Akt inhibitors.Type: ApplicationFiled: August 29, 2014Publication date: January 1, 2015Applicants: YALE UNIVERSITY, UNIVERSITY OF SOUTH FLORIDAInventors: Said M. Sebti, Jin Q. Cheng, Andrew D. Hamilton, Katherine Kayser-Bricker
-
Publication number: 20150004189Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.Type: ApplicationFiled: February 7, 2013Publication date: January 1, 2015Inventors: Alessandro Sette, Carla Oseroff, Howard Grey, Bjoern Peters
-
Patent number: 8921308Abstract: The instant invention refers to an antibacterial peptide with all amino acids in D-configuration, possessing strong antimicrobial activity against Gram-negative and Gram-positive bacteria and Candida strains. The peptide can be in linear form multimerised on a skeleton of polyacrylamide, of dextrane units or on a skeleton of ethylene glycol units. The peptide is resistant proteolysis especially when synthesized in the tetra-branched form where identical peptide sequences are linked together by an appropriate molecular scaffold.Type: GrantFiled: July 11, 2011Date of Patent: December 30, 2014Assignee: Setlance S.R.L.Inventors: Alessandro Pini, Chiara Falciani, Luisa Bracci
-
Patent number: 8921517Abstract: The present invention relates to a process for the production of bivalirudin, a 20-mer peptide of formula H-(D)-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH (SEQ ID NO: 1).Type: GrantFiled: December 17, 2009Date of Patent: December 30, 2014Assignee: Lonza Braine SAInventors: Geoffroy Sommen, Luciano Forni
-
Publication number: 20140377184Abstract: Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to tumors, sties of injury and blood clots in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tumors, sites of injury and blood clots.Type: ApplicationFiled: July 14, 2014Publication date: December 25, 2014Inventors: Erkki Ruoslahti, Jan Pilch
-
Publication number: 20140378655Abstract: Stabilization of water-containing solutions or lyophilizates of proteins and peptide against non-enzymatic deamidation degradation reactions at asparaginyl or glutaminyhl residues is achieved using organic anions, such as saccharin, benzenesulfonic acid, gentisic acide or N-acetyltryptophan which have a pKa within the range of 0.5 to 3.Type: ApplicationFiled: September 5, 2014Publication date: December 25, 2014Inventor: David Anderson
-
Publication number: 20140378654Abstract: The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.Type: ApplicationFiled: June 24, 2014Publication date: December 25, 2014Inventors: Stephen H. LEPPLA, Shi-Hui LIU, Sarah NETZEL-ARNETT, Henning BIRKEDAL-HANSEN, Thomas BUGGE
-
Publication number: 20140377801Abstract: The present invention relates to expression vectors and methods for enhancing soluble expression and secretion of an insoluble heterologous protein, particularly a bulky folded active heterologous protein which has one or more transmembrane-like domains or intramolecular disulfide bonds by linking a leader peptide with acidic or basic pl and high hydrophilicity thereto; by substituting one or more amino acids within N-terminal of the heterologous protein with ones having acidic or neutral pl and high hydrophilicity; or reducing elevating ?GRNA value of a polynucleotide encoding the leader peptide having basic pl value and high hydrophilicity. The expression vector and the method may be used to produce of heterologous protein and to transduce of therapeutic proteins in a patient by preventing formation of insoluble inclusion body and by enhancing secretional efficiency of the heterologous protein into the periplasm or outside cell.Type: ApplicationFiled: June 19, 2014Publication date: December 25, 2014Inventors: Sang Jun Lee, Young Ok Kim, Bo Hye Nam, Hee Jeong Kong, Kyung Kil Kim
-
Patent number: 8916681Abstract: The present invention relates to the use of an antagonist of kisspeptin in the manufacture of a medicament for the treatment of a condition induced and/or worsened by kisspeptin activity in an individual. The invention also provides certain defined peptide molecules, which may act as an antagonist of kisspeptin, which are of use in treating a condition induced and/or worsened by kisspeptin activity in an individual. In addition, the invention provides methods of identifying and/or using antagonists of kisspeptin and/or the defined peptides, and pharmaceutical compositions thereof.Type: GrantFiled: October 8, 2008Date of Patent: December 23, 2014Assignee: Medical Research CouncilInventors: Robert Peter Millar, Antonia Kathryn Roseweir
-
Publication number: 20140371150Abstract: The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.Type: ApplicationFiled: December 21, 2012Publication date: December 18, 2014Inventors: Dominique Heymann, Stéphane Teletchea, Verena Stresing
-
Publication number: 20140371161Abstract: The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof.Type: ApplicationFiled: January 16, 2013Publication date: December 18, 2014Applicant: Governing Council of The University of TorontoInventor: Paulo Koeberle